Personality Pharmacology

Part IV · Psychopathology on the Same Landscape Draft

Chapter 27

Drug-Induced Psychosis as Threshold Crossing

Why can one person use a psychoactive drug repeatedly without psychosis while another develops paranoia, hallucinations, or disorganization after an exposure that appears modest?

The wrong answer is that the drug either “causes psychosis” or does not.

The better answer is interaction.

Drug-induced psychosis is an unusually vivid example of the central law of personality pharmacology. A drug creates a perturbation. The person has a pre-existing vulnerability or resilience profile. Sleep, stress, age, developmental stage, dose, rate of exposure, prior sensitization, concurrent drugs, and environment all modify the effective state. Psychosis occurs when the combined system crosses a threshold for reliable reality integration.

This model does not require a single psychosis meter in the brain.

Different drugs can reach a similar clinical endpoint by different routes. Stimulants can increase dopaminergic salience and prolong wakefulness. Cannabis perturbs the endocannabinoid system and downstream excitatory, inhibitory, and dopaminergic processes. Psychedelics strongly alter serotonergic cortical signaling and the weighting of perception and prior models. Dissociatives disrupt NMDA-dependent integration. Corticosteroids can destabilize mood and sleep. Anticholinergic states can produce delirium with hallucinations and delusions through yet another mechanism.

Stimulantssalience and lost sleepCannabisendocannabinoid anddownstreamPsychedelicscortical serotoninsignallingDissociativesNMDA-dependentintegrationCorticosteroidsmood and sleepAnticholinergicsdeliriumA similar endpointpsychosis
Figure 27.1Different drugs, one endpoint. Psychosis can be reached by several pharmacological routes, which is why there is no single psychosis meter to watch.

The endpoint can resemble itself while the path differs.

Baseline matters within each path. A person with previous psychosis, strong schizotypal traits, family vulnerability, severe sleep sensitivity, chronic stress, or prior sensitization may require a smaller perturbation. Another person may tolerate a larger perturbation without crossing the same threshold.

The threshold itself can move.

Sleep deprivation lowers resilience. Stress increases arousal. Repeated stimulant exposure can sensitize responses. Adolescence and early adulthood may represent different developmental risk windows from later life. A supportive, predictable environment may reduce the probability that unusual experiences become threatening or self-reinforcing.

Rested, supported, stable integrationsame drug pushunstable regionAfter sleep loss, stress and sensitisationsame drug pushcrossed
Figure 27.2The threshold moves. The dose is never the whole exposure. Sleep, stress, history and surroundings set how close the edge already is. Illustrative model, not measured data.

This is why “the dose” is never the entire exposure.

The model can be pictured as a multidimensional distance to an unstable region. Imagine that salience is already elevated, sleep is poor, and model constraint is weak. A stimulant shifts salience further and removes another night’s sleep. The combined movement may be enough to push the system into paranoia. In another person with stable sleep and stronger integration, the same pharmacological perturbation remains below the transition boundary.

Once crossed, hysteresis becomes important. Psychosis can persist after the drug concentration has fallen. The system may have entered a self-sustaining state involving sleep disruption, fear, social feedback, altered beliefs, and continued arousal. Removing the original perturbation is necessary but not always sufficient.

Interactive figure: Threshold crossing.

Figure 27.3Threshold crossing. A vulnerable system can absorb rising exposure with little visible change, then cross into a new state that does not end the moment the trigger is removed. Illustrative model, not measured data.

This feature distinguishes drug-induced psychosis from a simple intoxication symptom.

The model also explains why the label “drug-induced” can be ambiguous. A substance may be a sufficient cause in one person, a trigger revealing an underlying vulnerability in another, or one contributor among several in a third. The causal attribution depends on counterfactuals we cannot always observe.

Would psychosis have occurred without the drug? Would it have occurred later? Did the drug create a new sensitized trajectory? These are clinical and forensic questions precisely because causation is interactional.

Personality enters through vulnerability dimensions rather than stereotypes. The relevant traits might include unusual perceptual experiences, suspiciousness, associative looseness, stress reactivity, sleep instability, or cognitive disorganization. None should be treated as destiny. Many people with unusual experiences never develop psychosis, and most psychoactive exposure does not lead to persistent psychotic illness.

A threshold model is probabilistic.

It also creates testable predictions. Baseline phenotypes should modify dose-response curves. Some risk markers should generalize across drug classes because they reflect common reality-integration vulnerability. Others should be mechanism-specific. Prior episodes should alter future risk. Sleep protection should reduce risk in some settings. Individual trajectories should be more informative than one cross-sectional measure.

The ethical relevance extends beyond recreational drugs. Dopaminergic medications, corticosteroids, prescribed stimulants, and other treatments can precipitate psychiatric states in vulnerable people. The same medicine can restore function in one patient and destabilize another.

This is personality pharmacology under high contrast.

If baseline × perturbation explains who develops psychosis, the same law is likely to operate more subtly for anxiety, emotional blunting, motivation, sociability, cognitive flexibility, and compulsive behavior. The outcome is less dramatic, but the architecture is the same.

The threshold model also encourages humility about drug labels. Calling a drug “psychotomimetic”, “anxiolytic”, or “prosocial” describes average tendencies or possible effects. It does not describe what the drug will do to a particular person in a particular state.

A psychoactive drug is not a destination. It is a force applied to a moving system.

The next part turns from involuntary destabilization to deliberate perturbation. Humans have been applying forces to their own minds for as long as culture has existed. The question is why.